Onkoloji Uzman\u0131 Prof. Dr. U\u011fur Co\u015fkun, meme kanserinde d\u00fcnyadaki son geli\u015fmelere de\u011findi. Co\u015fkun, “Art\u0131k anla\u015f\u0131lm\u0131\u015ft\u0131r ki meme kanseri tek tip bir hastal\u0131k de\u011fildir” dedi.<\/p>\n
T\u00fcrkiye\u2019de yayg\u0131nla\u015fan tarama programlar\u0131 ve modern cihazlar sayesinde meme kanserinin daha erken safhalarda yakaland\u0131\u011f\u0131n\u0131 belirten Co\u015fkun, erken te\u015fhis koyulan hastalar\u0131n b\u00fcy\u00fck \u00e7o\u011funlu\u011funun iyile\u015febildi\u011fini kaydetti.<\/p>\n
Son d\u00f6nemde geli\u015ftirilen yeni ila\u00e7larla hastal\u0131\u011f\u0131 ba\u015fka organlara yay\u0131lm\u0131\u015f olan hastalar\u0131n bir k\u0131sm\u0131n\u0131n da tamamen tedavi edilebildi\u011fini bildiren Co\u015fkun, “Eskiden kemik, akci\u011fer, karaci\u011fer gibi uzak organlara yay\u0131lma yapm\u0131\u015f hastalar tedavi edilemez gibi d\u00fc\u015f\u00fcn\u00fcl\u00fcrken, yeni geli\u015ftirilen ila\u00e7larla, hastalar\u0131n bir grubunda tamama yak\u0131n iyile\u015fmeler sa\u011flanabilmektedir. Art\u0131k anla\u015f\u0131lm\u0131\u015ft\u0131r ki meme kanseri tek tip bir hastal\u0131k de\u011fildir” dedi.<\/p>\n
Her bir alt grubun kanser geli\u015fiminde ve yay\u0131lmas\u0131nda, yolaklar\u0131n farkl\u0131 oldu\u011funu vurgulayan Co\u015fkun, \u015funlar\u0131 kaydetti:<\/p>\n
“Bu yolaklara kar\u015f\u0131 geli\u015ftirilen ak\u0131ll\u0131 ila\u00e7lar uygulanarak kemoterapide g\u00f6rd\u00fc\u011f\u00fcm\u00fcz yan etkiler g\u00f6r\u00fclmeden etkili ve uzun s\u00fcreli tedaviler uygulanmakta, eskisine g\u00f6re \u00e7ok daha iyi neticeler al\u0131nd\u0131\u011f\u0131n\u0131 g\u00f6rebiliyoruz. \u00d6zellikle baz\u0131 alt gruplardaki ilerlemeler o kadar h\u0131zl\u0131 olmaktad\u0131r ki, bu gruplarda ilerde yay\u0131lm\u0131\u015f hastal\u0131\u011f\u0131n tamamen tedavi edilebilece\u011fini s\u00f6ylemek ger\u00e7ek d\u0131\u015f\u0131 olmayacakt\u0131r.”<\/p>\n
Cerb-b2 molek\u00fcl\u00fcn\u00fcn, meme kanseri hastas\u0131nda y\u00fczde 15 ve y\u00fczde 25 aras\u0131nda pozitif oldu\u011funu s\u00f6yleyen Co\u015fkun, eskiden bu molek\u00fcl\u00fcn pozitifli\u011finin hastal\u0131\u011f\u0131n seyrinin \u00e7ok olumsuz olaca\u011f\u0131n\u0131n g\u00f6stergesi iken, g\u00fcn\u00fcm\u00fczde bu molek\u00fcle kar\u015f\u0131 geli\u015ftirilmi\u015f olan ila\u00e7larla bu hastalarda \u00e7ok iyi sonu\u00e7lar al\u0131nd\u0131\u011f\u0131na i\u015faret etti.<\/p>\n
Co\u015fkun, bu gruba kar\u015f\u0131 geli\u015ftirilmi\u015f olan \u2018trastuzumab\u2019 isimli molek\u00fcl erken evre hastalarda koruyucu ama\u00e7l\u0131 olarak kullan\u0131ld\u0131\u011f\u0131n da, metastaz geli\u015fimini b\u00fcy\u00fck oranda azalt\u0131rken, ba\u015fka organlara hastal\u0131\u011f\u0131 yay\u0131lm\u0131\u015f olan hastalarda da, hastal\u0131\u011f\u0131n tamamen kontrol al\u0131nmas\u0131n\u0131 sa\u011flayabildi\u011fini aktard\u0131.<\/p>\n
Kullan\u0131lan ilac\u0131n bazen, 5 veya 10 y\u0131l gibi uzun s\u00fcreli kullan\u0131mlar\u0131 hastalar\u0131n bir k\u0131sm\u0131nda \u00f6l\u00fcmc\u00fcl olmaktan \u00e7\u0131k\u0131p, kronik bir hastal\u0131\u011fa d\u00f6n\u00fc\u015ft\u00fc\u011f\u00fcn\u00fc kaydeden Co\u015fkun, “Cerb-b2 molek\u00fcl\u00fcn\u00fcn di\u011fer \u2019HER\u2019 ailesi resept\u00f6rleriyle etkile\u015fimini \u00f6nleyen \u2018pertuzumab\u2019 isimli di\u011fer bir ilac\u0131n ise daha sonradan geli\u015ftirildi\u011fini s\u00f6yleyebiliriz. Bu iki ajan\u0131n birlikte kullan\u0131ld\u0131\u011f\u0131nda adeta birbirini tamamlad\u0131\u011f\u0131n\u0131 ve hastalar \u00fczerinde olan ba\u015far\u0131n\u0131n daha da art\u0131\u011f\u0131n\u0131 s\u00f6yleyebiliriz” dedi.<\/p>\n
Alandaki geli\u015fmelerin bununla s\u0131n\u0131rl\u0131 kalmad\u0131\u011f\u0131n\u0131n alt\u0131n\u0131 \u00e7izen Co\u015fkun, \u015f\u00f6yle konu\u015ftu:<\/p>\n
“\u2018Trastuzumab\u2019 isimli ila\u00e7la bir kemoterapi ajan\u0131n\u0131n birle\u015ftirilmesi ile geli\u015ftirilen \u2018Ado-trastuzumab emtasine\u2019 isimli ila\u00e7 sadece t\u00fcm\u00f6r h\u00fccrelerinin i\u00e7erisine daha y\u00fcksek birim dozda kemoterapi uygulamas\u0131na imkan tan\u0131maktad\u0131r. Lapatinib, afatinib, neratinib gibi ayn\u0131 molek\u00fcl\u00fc hedef alan k\u00fc\u00e7\u00fck molek\u00fcll\u00fc ak\u0131ll\u0131 ila\u00e7larda geli\u015ftirilmi\u015f olup bu alandaki geli\u015fmeler \u00e7\u0131\u011f gibi b\u00fcy\u00fcmektedir. Bu ila\u00e7lar\u0131n meme kanseri d\u0131\u015f\u0131nda t\u00fcm\u00f6r h\u00fccreleri y\u00fczeyinde Cerb-B2 molek\u00fcl\u00fc ta\u015f\u0131yan di\u011fer kanser t\u00fcrlerinde de ara\u015ft\u0131rmas\u0131 devam etmektedir. \u00d6zellikle hastal\u0131\u011f\u0131 yay\u0131lm\u0131\u015f mide kanserli hastalarda \u00e7ok iyi sonu\u00e7lar al\u0131nd\u0131\u011f\u0131 g\u00f6r\u00fclmektedir.”<\/p>\n
Benzeri alanlarda, klinik ara\u015ft\u0131rmalar\u0131n\u0131n t\u00fcm d\u00fcnyada h\u0131zl\u0131 bir \u015fekilde devam etmekte oldu\u011funu bildiren Co\u015fkun, “\u00dclkemiz onkoloji doktorlar\u0131 taraf\u0131ndan da bu geli\u015fmeler \u00e7ok yak\u0131ndan takip edilmekte, pek uzak olmayan bir gelecekte meme kanseri geli\u015ftirilen ak\u0131ll\u0131 ila\u00e7larla \u00f6l\u00fcmc\u00fcl olmaktan \u00e7\u0131k\u0131p, tamamen kronik bir hastal\u0131\u011fa d\u00f6n\u00fc\u015fecektir” ifadelerini kulland\u0131.<\/p>\n","protected":false},"excerpt":{"rendered":"
ONKOLOJ\u0130 UZMANI PROF. DR. U\u011eUR CO\u015eKUN, MEME KANSER\u0130NDE D\u00dcNYADAK\u0130 SON GEL\u0130\u015eMELERE DE\u011e\u0130ND\u0130. CO\u015eKUN, “ARTIK ANLA\u015eILMI\u015eTIR K\u0130 MEME KANSER\u0130 TEK T\u0130P B\u0130R HASTALIK DE\u011e\u0130LD\u0130R” DED\u0130.<\/p>\n","protected":false},"author":1,"featured_media":69693,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[2058,13132,5460,2843,144],"class_list":["post-69692","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-genel","tag-artik","tag-edilebilir","tag-kanseri","tag-meme","tag-tedavi"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.tvturk.com\/wp-content\/uploads\/2019\/03\/meme-kanseri-artik-tedavi-edilebilir_876f3f0.jpg?fit=1000%2C666","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/paKIfm-i84","_links":{"self":[{"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/posts\/69692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/comments?post=69692"}],"version-history":[{"count":0,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/posts\/69692\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/media\/69693"}],"wp:attachment":[{"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/media?parent=69692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/categories?post=69692"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.tvturk.com\/index.php\/wp-json\/wp\/v2\/tags?post=69692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}